Preview

FOCUS. Endocrinology

Advanced search

Remission of type 2 diabetes mellitus in a patient with obesity and hypogonadism

https://doi.org/10.15829/2713-0177-2023-3-20

Abstract

Currently, obesity is the main risk factor for the development of type 2 diabetes mellitus (type 2 diabetes) as a key link in the emergence of insulin resistance. Traditionally, the basic strategy for controlling type 2 diabetes is to normalize blood glucose levels by correcting lifestyle and lifelong use of oral and/or injectable hypoglycemic therapy. However, in recent years, doctors and researchers are increasingly turning to the possibility of remission of type 2 diabetes. Remission of diabetes mellitus is the preservation of normal values of glycemia with the complete abolition of hypoglycemic therapy (tablet or injection). Many studies reflect that lifestyle changes, such as weight loss, dieting and increased physical activity, contribute to the onset of remission of type 2 diabetes in a significant number of people. In this clinical case, we demonstrate the possibility of achieving remission of diabetes mellitus with a multifactorial approach to the treatment of type 2 diabetes mellitus, which causes stabilization of blood glucose levels, prevention of complications and improvement of quality of life, and thus, we exhibit new prospects in the treatment of this disease.

About the Authors

E. Zh. Sargsyan
Pirogov Russian National Research Medical University
Russian Federation

Ellen Zh. Sargsyan – Resident of the Department of endocrinology, faculty of general medicine

117997, Moscow, 1 Ostrovityanova Str., Phone number: +79645923330  



D. V. Skuridina
Pirogov Russian National Research Medical University
Russian Federation

Darya V. Skuridina, assistant of the Department of endocrinology, faculty of general medicine 

117997, Moscow, 1 Ostrovityanova Str.



C. G. Lobanova
Pirogov Russian National Research Medical University
Russian Federation

Christina G. Lobanova, assistant of the Department of endocrinology, faculty of general medicine 

117997, Moscow, 1 Ostrovityanova Str.



References

1. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022 Aug;133:155217. doi: 10.1016/j.metabol.2022.155217.

2. Wondmkun YT. Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab Syndr Obes. 2020 Oct 9;13:3611–3616. https://doi.org/10.2147/DMSO.S275898.

3. GBD 2015 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1659–1724. doi: 10.1016/S0140-6736(16)31679-8.

4. John B. Buse, Sonia Caprio, William T. Cefalu, Antonio Ceriello et al. How Do We Define Cure of Diabetes?. Diabetes Care 1 November 2009; 32 (11): 2133–2135. https://doi.org/10.2337/dc09–9036.

5. Lean, M. E., Leslie, W. S., Barnes et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018 Feb 10;391(10120):541–551. doi: 10.1016/S0140-6736(17)33102-1.

6. Rock, C. L., Flatt, S. W., Pakiz, B. et al. Weight loss, glycemic control, and cardiovascular disease risk factors in response to differential diet composition in a weight loss program in type 2 diabetes: a randomized controlled trial. Diabetes Care. 2014 Jun;37(6):1573–80. doi: 10.2337/dc13-2900.

7. Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова 11-й выпуск – М.;2023 doi: https://doi.org/10.14341/DM13042 [Dedov I.I., Shestakova M.V., Mayorov A.Y. et al. Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th edition – М.;2023 doi: https://doi.org/10.14341/DM13042]

8. Lakshman KM, Basaria S. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Clin Interv Aging. 2009;4:397–412. doi: 10.2147/cia.s4466. Epub 2009 Nov 18. PMID: 19966909; PMCID: PMC2785864.].


Supplementary files

Review

For citations:


Sargsyan E.Zh., Skuridina D.V., Lobanova C.G. Remission of type 2 diabetes mellitus in a patient with obesity and hypogonadism. FOCUS. Endocrinology. 2023;4(3):80-84. (In Russ.) https://doi.org/10.15829/2713-0177-2023-3-20

Views: 201


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2713-0177 (Print)
ISSN 2713-0185 (Online)